| Title : Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes - Deacon_2008_Curr.Opin.Investig.Drugs_9_402 |
| Author(s) : Deacon CF |
| Ref : Curr Opin Investig Drugs , 9 :402 , 2008 |
|
Abstract :
Takeda San Diego Inc is developing alogliptin, a small-molecule, orally available dipeptidyl peptidase IV (DPP IV) inhibitor, for the potential treatment of type 2 diabetes. In January 2008, Takeda announced that an NDA for alogliptin had been submitted to the FDA. |
| PubMedSearch : Deacon_2008_Curr.Opin.Investig.Drugs_9_402 |
| PubMedID: 18393107 |
| Inhibitor | Alogliptin |
Deacon CF (2008)
Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes
Curr Opin Investig Drugs
9 :402
Deacon CF (2008)
Curr Opin Investig Drugs
9 :402